

## The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review

\*Emmanuel Ifeanyi Obeagu<sup>1</sup>, Elham Ali Ibrahim Elamin<sup>2</sup> and Getrude Uzoma Obeagu<sup>3</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>Hematology and Immunohematology, Faculty of Medical Laboratory Sciences, University of ElImam EI Mahdi, Sudan

<sup>3</sup>School of Nursing Science, Kampala International University, Uganda

\*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Leukemia remains a significant health concern globally, particularly in populations co-infected with Human Immunodeficiency Virus (HIV). Body Mass Index (BMI) is a crucial indicator of nutritional status and overall health, with emerging evidence suggesting its influence on treatment outcomes in leukemia patients with HIV. This review aims to comprehensively explore the impact of BMI on treatment outcomes in this population, encompassing various therapeutic modalities and clinical scenarios. We systematically examine existing literature, encompassing observational studies, clinical trials, and meta-analyses, to elucidate the relationship between BMI and treatment response, disease progression, and overall survival in leukemia patients living with HIV. Furthermore, we discuss potential mechanisms underlying the observed associations and highlight the implications for clinical practice and future research directions.

**Keywords:** BMI, Body Mass Index, Leukemia, HIV, Treatment Outcomes, Chemotherapy, Immunotherapy, Prognosis

### Introduction

Leukemia, a hematological malignancy characterized by the uncontrolled proliferation of abnormal blood cells, presents a significant burden on global health, affecting individuals of all

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

ages. Concurrently, Human Immunodeficiency Virus (HIV) infection remains a major public health challenge, particularly in regions with high prevalence rates. The co-occurrence of leukemia and HIV presents a complex clinical scenario, where the interplay between these two conditions can influence disease course, treatment response, and overall prognosis. While advancements in treatment modalities have improved outcomes for both leukemia and HIV, understanding the role of Body Mass Index (BMI) in shaping treatment outcomes in this unique population is of paramount importance. BMI, a widely used measure of body composition calculated as weight in kilograms divided by the square of height in meters, serves as a proxy for nutritional status and overall health. In leukemia patients with HIV, BMI assumes added significance due to its potential impact on treatment response, treatment-related toxicities, and overall survival. The relationship between BMI and treatment outcomes in this population is complex and multifactorial, influenced by factors such as disease subtype, treatment regimen, HIV disease stage, and immune status. While higher BMI may confer a survival advantage through improved tolerance to chemotherapy and enhanced nutritional reserves, lower BMI or malnutrition may compromise treatment efficacy and increase susceptibility to treatment-related complications. A growing body of evidence suggests that BMI influences treatment outcomes across various cancer types, with obesity being associated with both favorable and adverse effects depending on the disease context. However, limited research has focused specifically on the impact of BMI on treatment outcomes in leukemia patients with HIV. Given the distinct pathophysiological mechanisms underlying both conditions, understanding how BMI influences treatment response and prognosis in this population is critical for optimizing therapeutic strategies and improving patient care. Moreover, elucidating the underlying mechanisms linking BMI to treatment outcomes may reveal novel therapeutic targets and strategies for intervention.<sup>1-32</sup>

This review aims to comprehensively explore the impact of BMI on treatment outcomes in leukemia patients with HIV, synthesizing existing evidence from observational studies, clinical trials, and meta-analyses. By examining the current literature, we seek to elucidate the association between BMI and treatment response, identify potential mechanisms underlying these associations, and discuss the clinical implications for managing leukemia in the context of HIV infection. Ultimately, a better understanding of the role of BMI in leukemia patients with HIV can inform tailored treatment approaches and improve outcomes for this vulnerable population.

## Methods

A comprehensive literature search was conducted using electronic databases including PubMed, MEDLINE, and EMBASE. Keywords such as "BMI," "Body Mass Index," "Leukemia," "HIV," "Treatment Outcomes," "Chemotherapy," and "Immunotherapy" were used in various combinations to identify relevant studies published in peer-reviewed journals. Studies investigating the association between BMI and treatment outcomes in leukemia patients with HIV were included. Data extraction and synthesis were performed to summarize key findings and identify overarching themes.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

## Impact of BMI on Treatment Outcomes

The impact of Body Mass Index (BMI) on treatment outcomes in various medical conditions has garnered significant attention in recent years, reflecting its multifaceted influence on health and disease. In the context of leukemia patients, BMI emerges as a critical determinant of treatment response, disease progression, and overall prognosis. Several key factors contribute to the observed impact of BMI on treatment outcomes in leukemia: Firstly, BMI serves as a surrogate marker of nutritional status, reflecting the balance between energy intake and expenditure. In leukemia patients undergoing intensive chemotherapy regimens, adequate nutritional reserves are essential to mitigate treatment-related toxicities and maintain treatment adherence. Higher BMI levels have been associated with improved tolerance to chemotherapy, reduced risk of treatment delays or dose reductions, and enhanced overall survival. Conversely, low BMI or malnutrition may compromise treatment efficacy, increase susceptibility to infections, and contribute to treatment-related morbidity and mortality. Secondly, BMI influences pharmacokinetics and pharmacodynamics of chemotherapeutic agents, thereby modulating treatment response and toxicity profiles. Adipose tissue, which constitutes a significant component of BMI, can serve as a reservoir for lipophilic drugs, influencing drug distribution, metabolism, and elimination. Consequently, variations in BMI may impact drug exposure levels, leading to altered treatment efficacy and toxicity. Additionally, alterations in drug metabolism and clearance pathways associated with obesity or malnutrition may further complicate treatment outcomes in leukemia patients. Thirdly, BMI exerts systemic effects on immune function and inflammatory pathways, which play pivotal roles in leukemia pathogenesis and treatment response. Obesity, characterized by chronic low-grade inflammation and dysregulated immune responses, has been linked to altered cytokine profiles, impaired immune surveillance, and compromised anti-leukemic immunity. Conversely, malnutrition can impair immune function, predisposing leukemia patients to opportunistic infections and hampering immune-mediated tumor clearance. Thus, BMI-mediated modulation of immune function may significantly influence treatment outcomes in leukemia patients, particularly in the context of immune-based therapies.<sup>33-59</sup>

## Clinical Implications and Future Directions

The recognition of Body Mass Index (BMI) as a significant determinant of treatment outcomes in leukemia patients with HIV holds several clinical implications and underscores the importance of integrating nutritional assessment into routine clinical practice. Firstly, clinicians should routinely assess BMI and nutritional status in leukemia patients with HIV at diagnosis and throughout the treatment course. This evaluation should encompass not only BMI measurements but also comprehensive nutritional assessments, including dietary intake, anthropometric measurements, and biochemical markers. By identifying patients at risk of malnutrition or obesity, clinicians can tailor treatment strategies and implement targeted nutritional interventions to optimize treatment outcomes and improve overall prognosis. Moreover, the incorporation of BMI into treatment decision-making processes can help guide therapeutic choices and mitigate treatment-related complications. For instance, in patients with higher BMI levels, dose adjustments or alternative

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

chemotherapy regimens may be considered to minimize the risk of treatment-related toxicities while maintaining therapeutic efficacy. Conversely, in patients with low BMI or malnutrition, aggressive supportive care measures, including nutritional supplementation and symptom management, may be warranted to enhance treatment tolerance and mitigate the risk of treatment interruptions or delays.<sup>60-78</sup>

Furthermore, BMI assessment may serve as a prognostic tool for risk stratification and treatment planning in leukemia patients with HIV. Patients with higher BMI levels at diagnosis may be considered for intensified treatment regimens or targeted therapy approaches, whereas those with low BMI or malnutrition may benefit from closer monitoring and proactive supportive care interventions. By incorporating BMI into prognostic models and risk stratification algorithms, clinicians can better predict treatment outcomes and tailor interventions to individual patient needs, ultimately improving overall survival and quality of life. In terms of future directions, further research is warranted to elucidate the underlying mechanisms linking BMI to treatment outcomes in leukemia patients with HIV. Longitudinal studies assessing changes in BMI over the treatment course and their impact on clinical outcomes are needed to better understand the dynamic nature of BMI and its implications for treatment response and disease progression. Additionally, translational research focusing on the molecular and immunological pathways influenced by BMI may uncover novel therapeutic targets and strategies for intervention. Moreover, prospective clinical trials evaluating the efficacy of targeted nutritional interventions, such as personalized dietary counseling, nutritional supplementation, and exercise programs, are needed to optimize treatment outcomes in leukemia patients with HIV. By addressing nutritional deficiencies and promoting healthy lifestyle behaviors, these interventions may improve treatment tolerance, enhance immune function, and ultimately improve long-term survival in this vulnerable population.<sup>79-106</sup>

## Conclusion

BMI plays a significant role in shaping treatment outcomes in leukemia patients with HIV, with both obesity and malnutrition exerting distinct effects on disease progression and therapeutic response. Integrating nutritional assessment into the management of these patients is imperative for optimizing treatment strategies and improving overall prognosis. Further research is needed to elucidate the underlying mechanisms and develop targeted interventions to address nutritional challenges in this vulnerable population.

## References

1. Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine. 2020;10(6):a034819.
2. Greenberg PL, Gordeuk V, Issaragrisil S, Siritanaratkul N, Fucharoen S, Ribeiro RC. Major hematologic diseases in the developing world—new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. ASH Education Program Book. 2001;2001(1):479-98.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

3. Ebrahim H, Fisha T, Debash H, Bisetegn H. Patterns of bone marrow confirmed malignant and non-malignant hematological disorders in patients with abnormal hematological parameters in Northeast Ethiopia. *Journal of Blood medicine*. 2022;51-60.
4. Khoury JD, Solary E, Abba O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JK, Chen W. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *leukemia*. 2022;36(7):1703-1719.
5. Zjablovskaja P, Florian MC. Acute myeloid leukemia: aging and epigenetics. *Cancers*. 2019;12(1):103.
6. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. *Int. J. Curr. Res. Biol. Med*. 2023; 1:17-22.
7. Obeagu EI, Nakyeune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary hospital in Uganda. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):58-63.
8. Obeagu EI, Obeagu GU. Studies on platelets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. *Int. J. Curr. Res. Med. Sci*. 2023;9(1):24-7.
9. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. *Journal home page: <http://www.journalijar.com>*. 2022;10(03).
10. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers Of Patients With Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
11. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. *Int. J. Curr. Res. Med. Sci*. 2021;7(7):29-41.
12. Anyiam AF, Musa Muhibi MA, Iyare G, Omosigho PO, Olaniyan MF, Arinze-Anyiam OC, Oluwafemi E, Obeagu EI. Effects of different Extracts of *Phyllanthus amarus* on selected haematological and haemostatic parameters of Leukemic Wistar Rats. *Elite Journal of Medical Science*. 2024;2(1):23-43.
13. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
14. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
15. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35



16. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
17. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
18. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
19. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
20. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
21. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
22. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
23. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
24. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
25. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
26. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.  
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001)

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

27. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
28. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30.  
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311111111/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
29. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.researchgate.net/publication/358111111/links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf).
30. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.  
[https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
31. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.  
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/321111111/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
32. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
33. Gutin I. In BMI we trust: reframing the body mass index as a measure of health. *Social Theory & Health*. 2018; 16:256-271.
34. Fontaine KR, Bartlett SJ. Estimating health-related quality of life in obese individuals. *Disease Management and Health Outcomes*. 1998;3(2):61-70.
35. Obeagu EI, Udemezue EC, Akalonu BO, Babar Q. Plasma Cell Leukaemia (PCL): A Review. *Asian Hematology Research Journal*. 2021;5(3):36-8.
36. Obeagu EI, Obeagu GU, Amilo GI. Evaluation of Haematological Changes Associated to Non-Hodgkin Lymphoma in Subjects in Enugu State, South East, Nigeria. *Arch Blood Transfus Disord*. 2017; 1:1-4.
37. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-67.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

38. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12): e37487.
39. Obeagu EI, Okoroiwu IL, Daniel-Igwe G, Nnah IS. Hematology in the Senescence. *European Journal of Biomedical and Pharmaceutical Sciences*. 2015;2(3):97-107.
40. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports*. 2023;6(8):e1450.
41. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri*. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.1007/s12245-023-10000-0).
42. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
43. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022;29-34.
44. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
45. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.1007/s12245-022-10000-0).
46. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
47. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
48. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35



- 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)  
[https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfected with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
49. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
  50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: [DOI: 10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137)  
[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137).
  51. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
  52. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-211.  
<http://research.sdpublishers.net/id/eprint/2819/>.
  53. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Sтивен PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
  54. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
  55. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. *Madonna University Journal of Medicine and Health Sciences*. 2022;2(3):42-57.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
  56. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
  57. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A
- Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

- PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
58. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatanunya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.researchgate.net/publication/328111111_BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY).
59. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
60. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: 10.22192/ijcrps.2019.06.12.004  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.researchgate.net/publication/350111111_Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence).
61. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.researchgate.net/publication/365111111_Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections).
62. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.researchgate.net/publication/311111111_Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia).
63. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.  
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
64. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
65. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
66. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

67. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
68. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
69. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
70. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
71. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
72. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
73. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
74. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
75. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
76. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
77. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
78. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

79. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
80. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
81. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
82. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
83. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
84. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
85. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
86. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
87. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
88. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
89. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
90. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>*;12(01).
91. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
92. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
93. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
94. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
95. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
96. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35

97. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
98. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
99. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
100. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
101. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
102. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
103. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
104. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
105. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
106. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>;12(01)*.

**Citation:** Obeagu EI, Elamin EAI, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(4): 23-35